IDbyDNA raises $20M in Series B funding for Explify diagnosis platform
Category: #business  By Anchal Solanki  Date: 2020-01-31
  • share
  • Twitter
  • Facebook
  • LinkedIn
IDbyDNA raises $20M in Series B funding for Explify diagnosis platform

 

  • The Series B funding has reportedly been led by ARTIS Ventures and others.
  • Main motive of the funding raised is to fuel growth of company’s Explify Software Platform for the treatment of global infectious diseases.
     

California based metagenomics technology company, IDbyDNA has recently announced raising nearly USD 20 million in the Series B funding for carrying out the developments in the pathogen identification and infectious disease detection. Moreover, it has been claimed that the funding was led by ARTIS Ventures joined by Genesys Capital and various others.

According to credible sources, funds generated would be used to drive the growth of IDbyDNA’s Explify Software Platform for the global infectious disease and microbe testing industries. For the records, Explify identifies approximately more than 20 thousand microorganisms and 3 thousand rare and known pathogens. Additionally, company’s current partnerships and collaborations with the leading US and worldwide commercial labs, academic institutions, and hospitals would augment the customer adoption of Explify as one of the leading metagenomics technology platforms.

 It has been reported that the Series B funding would also be used to support the launch of CLIA-approved commercial lab at the company’s Salt Lake City facility. Speculations have it that platform’s capabilities will gain profit from this facility’s disease testing.

Guochun Liao, the co-founder and CEO of IDbyDNA reportedly quoted that the company will progressively enhance and expand its platform to facilitate the testing procedures of pathogens and microorganisms.

Meanwhile, a partner at ARTIS Ventures, Stuart Peterson, cited that the management believes in company’s technology which has hit a tipping point and is now all set to revolutionize the way it responds and tackles the antimicrobial resistance and infectious disease outbreaks. He further added that being an investor in the company’s Series A Funding round as well, the firm stood chances of being a witness to the incredible insights of IDbyDNA’s approach to metagenomic testing to enhance the infectious disease diagnosis and pathogen detection.

Source credit: https://www.biospace.com/article/releases/idbydna-raises-20-million-in-series-b-financing-to-continue-advancements-in-infectious-disease-diagnosis-and-pathogen-identification/
 

  • share
  • Twitter
  • Facebook
  • LinkedIn

About Author

Anchal Solanki

Anchal Solanki    

A civil engineer by qualification, Anchal Solanki forayed into the domain of content writing in the midst of her graduation, embarking on the career path of a successful freelancer. Equipped with a short-term experience in market research, Anchal currently writes news...

Read More >>

More News By Anchal Solanki

Open Systems inks an acquisition deal with Born in the Cloud
Open Systems inks an acquisition deal with Born in the Cloud
By Anchal Solanki

Open Systems, a secure access service edge (SASE) solution company based out in Switzerland, has recently announced that it has purchased Born in the Cloud, a Microsoft Gold-Certified partner company that provides threat prevention, detection, and re...

PG&E announces plans to expand battery energy storage capacity
PG&E announces plans to expand battery energy storage capacity
By Anchal Solanki

Pacific Gas and Electric Company, the American combined natural gas and electric service company, has reportedly filed an application to CPUC (California Public Utilities Commission) for getting approval on five energy storage projects. Sources cite...

Siemens Gamesa introduces 14 MW offshore wind turbine with 222m rotor
Siemens Gamesa introduces 14 MW offshore wind turbine with 222m rotor
By Anchal Solanki

Non-exhaustible energy sources have evolved as one of the best alternative energy sources and have gained recognition and importance on a global scale. Having understood their exceptional advantages over traditional power sources, companies worldwide...